The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥ ...

Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥ ...

Nucala Becomes First Biologic Approved for COPD with Eosinophilic Inflammation The FDA’s approval of GSK’s Nucala (mepolizumab) introduces the first biologic treatment for patients with chronic ...

First approved in 2015, Nucala is a monoclonal antibody, meaning it recruits your body’s immune system to fight disease. It helps reduce inflammation by targeting a protein called interleukin-5 ...

GSK (GSK) stock gains as FDA broadens the label for the company's asthma therapy Nucala l for COPD with an eosinophilic phenotype. Read more here.

Company News Published 05/22/2025, 04:20 PM 0 FDA approves Nucala for eosinophilic COPD treatment GSK -0.09% ...

Nucala also cut patients’ yearly rate of exacerbations leading to emergency room visits and hospitalizations by 35% in one of the trial’s main secondary endpoints, GSK added.